Abstract:Multidrug resistance in bacterial pathogens poses a threat to human health, and the emergence of carbapenem-resistant Enterobacterales (CRE) infections seriously affects population welfare. The emergence of carbapenem resistance is a major concern, especially for intensive care units (ICUs) and other at high-risk wards, that has led to serious consequences (Tamman et al., 2021). Detailed studies identifying the mechanisms leading to carbapenem resistance in bacteria may help overcome and manage this issue (Mascellino et al., 2024). CRE often carry multiple resistance genes that are able to propagate through both vertical and horizontal routes (Rumbo et al., 2011). These resistance elements limit treatment options and some patients require a longer duration of therapy requiring intensive care with increased toxicities if compared to patients infected with carbapenem-susceptible strains. Therefore, new alternative approaches are needed to combat the spread of antimicrobial resistance in bacteria among populations and to treat patients infected with life-threatening carbapenem-resistant gram-negative bacteria (Oliva et al.,2021;Tompkins et al., 2021). The development of new classes of antibiotics could be a solution. However the director of World Health Organization (WHO) Dr. Tedros Adhanom Ghebreyesus said verbatim that "Since mid-2017, only 13 new antibiotics have been authorized, with just two representing a new chemical class and considered innovative" Molecular studies play an important role in understanding the mechanisms underlying bacterial resistance. For example, mobile colistin resistance genes (mcr-1 to mcr-10) and their variants have been identified in gram-negative bacteria which pose a new threat to the treatment of clinical infections. A new method using a multiplex TaqMan real-time PCR assay was developed to detect mobile colistin resistance genes. This method has high specificity, sensitivity, and reproducibility. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2024.1279186/full.A previous study examined the in vitro drug susceptibilities of Klebsiella pneumoniae strains producing New Delhi metallo-β-lactamases in Poland. Cefiderocol, eravacycline, tigecycline, ceftazidime/avibactam (CAZ/AVI) and aztreonam were found to be the most effective antibiotics, demonstrating CAZ/AVI plus aztreonam 100% in vitro sensitivity with the tested strains. Owing to the safety of both drugs and their cost-effectiveness, this therapy should be the first-line treatment for carbapenemase-producing Enterobacterales infections. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2024.1331628/full. Ginkgolic acid, derived from Ginko biloba extracts, was identified as a potent inhibitor against KPC-2 and found to have no toxic effects. The evolution of resistance genes has limited the clinical application of carbapenems. Therefore, the synergistic effect of ginkgolic acid and carbapenems, especially meropenem, could be interesting and valid in the fight against antimicrobial resistance, potentiating the killing effect of carbapenems on KPC-2positive Klebsiella pneumoniae. Generally, plant extracts exhibit good efficacy against microorganisms, specifically by altering the functional groups of KPC-2. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2024.1426603/full From a study conducted in Portugal, extensively drug-resistant Pseudomonas aeruginosa (PA) is a growing concern because of its resistance to most common antibiotics, including carbapenems, piperacillin-tazobactam, third-and fourth-generation cephalosporins, aminoglycosides, and fluoroquinolones. Only one case of non-susceptibility to colistin has been previously reported. Isolates were susceptible to ceftazidime-avibactam and ceftolozane-tazobactam in 71.5% and 77.5% of tested isolates, respectively. When a combination therapy is used, ceftazidime-avibactam plus colistin is preferred, which leads to a lower mortality rate in patients with PA infections.. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2024.1347521/full A network meta-analysis from South Arabia included data from over 25 clinical trials and 5,034 individuals to investigate the antibiotic resistance trends and treatment outcomes of gram-negative infections. Pseudomonas aeruginosa and Acinetobacter baumannii turned out to be more resistant than Enterobacterales. Meropenem has emerged as the preferred carbapenem agent, and the combination of meropenem and levofloxacin is the recommended first-line therapy for the carbapenem-resistant bacterial infections.. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2023.1304011/full In China, resistance of Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii was evaluated by comparing strains isolated in ICUs with those isolated from non-ICUs over a period of 10 years. Se -Abstract Truncated-

In Vivo Adaptive Antimicrobial Resistance in Klebsiella Pneumoniae During Antibiotic Therapy

The Rapid Emergence of Tigecycline Resistance in bla KPC-2 Harboring Klebsiella pneumoniae , as Mediated in Vivo by Mutation in tetA During Tigecycline Treatment.

In Vivo Emergence Of Colistin Resistance In Carbapenem-Resistant Klebsiella Pneumoniae Mediated By Premature Termination Of The Mgrb Gene Regulator

Tigecycline resistance caused by rpsJ evolution in a 59-year-old male patient infected with KPC-producing Klebsiella pneumoniae during tigecycline treatment

Emergence of Ceftazidime/Avibactam and Tigecycline Resistance in Carbapenem-Resistant Klebsiella Pneumoniae Due to In-Host Microevolution

<i>In vivo</i> Selection of Imipenem Resistance Among Ceftazidime-Avibactam-Resistant, Imipenem-Susceptible <i>Klebsiella pneumoniae</i> Isolate With KPC-33 Carbapenemase

In Vivo Evolution of Carbapenem Resistance in Hypervirulent Klebsiella Pneumoniae in a Patient Undergoing Long-Term Treatment

Evolution Of Tigecycline- And Colistin-Resistant Crkp (Carbapenem-Resistant Klebsiella Pneumoniae) In Vivo And Its Persistence In The Gi Tract

In vivo Emergence of Colistin and Tigecycline Resistance in Carbapenem-Resistant Hypervirulent Klebsiella pneumoniae During Antibiotics Treatment

Complex evolutionary trajectories in vivo of two novel KPC variants conferring ceftazidime-avibactam resistance

Evolving resistance landscape in gram-negative pathogens: An update on β-lactam and β-lactam-inhibitor treatment combinations for carbapenem-resistant organisms

Reduced Virulence and Enhanced Host Adaption during Antibiotics Therapy: a Story of a Within-Host Carbapenem-Resistant Klebsiella pneumoniae Sequence Type 11 Evolution in a Patient with a Serious Scrotal Abscess

Dynamic evolution of ceftazidime-avibactam resistance from a single patient through the IncX3_NDM-5 plasmid transfer and blaKPC mutation

In vivo divergent evolution of cross-resistance to new β-lactam/β-lactamase inhibitor combinations in Pseudomonas aeruginosa following ceftazidime/avibactam treatment

Reduced virulence and enhanced host adaption during antibiotics therapy: A story of a within-host carbapenem-resistant Klebsiella pneumoniae sequence type 11 evolution in a fatal scrotal abscess patient

Reduced virulence and enhanced host adaption during antibiotics therapy: A story of a within-host carbapenem-resistant <i>Klebsiella pneumoniae</i> sequence type 11 evolution in a fatal scrotal abscess patient

Adaptive evolution of virulence and persistence in carbapenem-resistant Klebsiella pneumoniae

Resistance evolution of hypervirulent carbapenem-resistant Klebsiella pneumoniae ST11 during treatment with tigecycline and polymyxin

Editorial: New therapeutic strategies against carbapenem-resistant gram-negative bacteria

Emergence of high-level colistin resistance mediated by multiple determinants, including <i>mcr-1.1</i>, <i>mcr-8.2</i> and <i>crrB</i> mutations, combined with tigecycline resistance in an ST656 <i>Klebsiella pneumoniae</i>

Dynamic evolution of ceftazidime–avibactam resistance due to interchanges between blaKPC-2 and blaKPC-145 during treatment of Klebsiella pneumoniae infection